Similar Papers

Paper Title
Journal
Date
Author
Moxetumomab pasudotox for the treatment of relapsed and/or refractory hairy cell leukemia
Iman Abou Dalle ... Farhad Ravandi
Expert Review of Hematology | VOL. 12
Iman Abou Dalle, et. al.Iman Abou Dalle ... Farhad Ravandi
01 Aug 2019
First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl
Jae H Park ... Martin S Tallman
Blood | VOL. 134
Jae H Park, et. al.Jae H Park ... Martin S Tallman
13 Nov 2019
Phase I Dose-Escalation Study of CAT-8015 (HA22), A CD22-Specific Targeted Immunotoxin, in Relapsed or Refractory Hairy Cell Leukemia.
Robert J Kreitman ... Ira Pastan
Blood | VOL. 114
Robert J Kreitman, et. al.Robert J Kreitman ... Ira Pastan
20 Nov 2009
A Phase 1 Study of Moxetumomab Pasudotox, An Anti-CD22 Recombinant Immunotoxin, In Relapsed/Refractory Hairy Cell Leukemia (HCL): Updated Results
Robert J Kreitman ... Ira Pastan
Blood | VOL. 116
Robert J Kreitman, et. al.Robert J Kreitman ... Ira Pastan
19 Nov 2010
View more papers

More From: Cancer discovery

Paper Title
Journal
Date
Author
PIN1 prolyl isomerase promotes initiation and progression of bladder cancer through the SREBP2-mediated cholesterol biosynthesis pathway.
Xue Wang ... Tony Hunter
Cancer discovery | VOL. -
Xue Wang, et. al.Xue Wang ... Tony Hunter
14 Jan 2025
Highlighted Research Articles
-
Cancer Discovery | VOL. 15
--
13 Jan 2025
Cancer Neuroscience of Brain Tumors: From Multicellular Networks to Neuroscience-Instructed Cancer Therapies.
Varun Venkataramani ... Frank Winkler
Cancer discovery | VOL. 15
Varun Venkataramani, et. al.Varun Venkataramani ... Frank Winkler
13 Jan 2025
Conquering Overtreatment of DCIS: Lessons from PRECISION.
Proteeti Bhattacharjee ...
Cancer discovery | VOL. 15
Proteeti Bhattacharjee, et. al.Proteeti Bhattacharjee ...
13 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.